The United States Food and Drug Administration approves the first generic version of lenacapavir, a

The United States Food and Drug Administration approves the first generic version of lenacapavir, a twice-yearly HIV prevention injection expected to cost about US$40 annually in 120 low- and middle-income countries. [https://www.france24.com/en/live-news/20261102-us-approves-cheap-generic-of-breakthrough-hiv-shot-for-poorer-countries (AFP via France 24)]

Event summary via Wikipedia Current Events (2026-11-02).